Table 3.
Univariate and Multivariate Analyses of Prognostic Factors for Overall Survival of Patients With Sorafenib-Refractory Advanced HCC.
| Factors | Overall Survival | |||
|---|---|---|---|---|
| Univariate | Multivariate | |||
| P Value | HR | 95% CI | P Value | |
| Gender (M/F) | .557 | |||
| Age, years | .283 | |||
| Cirrhosis (present/absent) | .026 | 0.354 | 0.103-1.222 | .101 |
| ALT (≤40/>40) | .744 | |||
| Albumin (<35/≥35) | .050 | 0.396 | 0.152-1.030 | .058 |
| Bilirubin (≤20/>20) | .211 | |||
| GGT (≤100/>100) | .068 | 1.395 | 0.613-3.178 | .428 |
| Ascites (present/absent) | .126 | |||
| Child-Pugh (A/B) | .059 | 2.172 | 0.538-8.766 | .276 |
| ECOG (0/1) | .729 | |||
| AFP (≤400/>400) | .912 | |||
| Liver tumor burden (≥50%/<50%) | <.001 | 1.543 | 1.067-2.598 | .001 |
| No. of tumors (1-3/>3) | .129 | |||
| PVTT (present/absent) | .001 | 2.695 | 1.783-3.457 | .104 |
| Extrahepatic metastases (present/absent) | <.001 | 0.235 | 0.106-0.795 | .013 |
Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; F, female; GGT, γ-glutamyl transpeptidase; HCC, hepatocellular carcinoma; HR, hazard ratio; M, male; PVTT, portal vein tumor thrombosis.